Lupin Ltd — Capital/Financing Update 2018

Dec 10, 2018

Press Release

==> picture [45 x 55] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin receives tentative US FDA approval for Apixaban Tablets, 2.5 mg and 5 mg

Mumbai, Baltimore, December 10, 2018: Pharma major Lupin announced that it has received tentative approval for its Apixaban Tablets, 2.5 mg and 5 mg from the United States Food and Drug Administration (FDA) to market a generic version of Bristol-Myers Squibb Company’s Eliquis® Tablets, 2.5 mg and 5 mg.

Lupin’s Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company’s Eliquis® Tablets, 2.5 mg and 5 mg. It is indicated for:

• reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

• prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), following hip or knee replacement surgery.

• treatment of DVT and PE and

• reducing the risk of recurrent DVT and PE.

Eliquis® Tablets, 2.5 mg and 5 mg had annual sales of approximately USD 6366 million in the US (IQVIA MAT September 2018).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 13[th] largest generics pharmaceutical company in terms of market capitalization (30[th] September 2018, Bloomberg) and the 8[th] largest generics pharmaceutical company in terms of revenues (30[th] June 2018, Bloomberg LTM) globally. The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT September 2018); 3[rd] largest Indian pharmaceutical company by global revenues (30[th] June 2018, Bloomberg LTM); 6[th] largest generic pharmaceutical player in Japan (IQVIA MAT September 2018) and 5[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2018).

For the financial year ended 31[st] March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66402137

*Safe Harbor Statement

Eliquis® Tablets, 2.5 mg and 5 mg is a registered trademark of Bristol-Myers Squibb Company (BMS)